Investors

Shareholder Information

Shares Issued

The number of ordinary shares in issue are 169,117,640.

Major shareholders (as at 30 June 2017)

Shareholders holding more than 3% of the share capital of the Company were:

Shareholder Number of
shares
held
% issued
share
capital
Legal & General Investment Management 25,469,135 15.06%
Harwood Capital* 25,000,000 14.78%
Schroder Investment Management 14,624,383 8.65%
Fidelity International 10,515,930 6.22%
Aviva Investors 8,200,328 4.85%
Cavendish Asset Management 7,975,865 4.72%
Janus Henderson Investors 6,602,092 3.90%
Milton Asset Management 5,551,297 3.28%
Brian George Kennedy 5,163,134 3.05%

Where applicable, shares held are direct and indirect holdings.
* Harwood Capital's shareholding of 25,000,000 ordinary shares includes 10,000,000 ordinary shares in which North Atlantic Smaller Companies Investment Trust plc is interested and 15,000,000 ordinary shares in which Oryx International Growth Fund Limited is interested of which 5,000,000 ordinary shares are registered in the name of Securities Services Nominees Limited (see Director shareholdings below).

Director Shareholdings

  Shares Held %
Gerard Murray 200,000 0.12
Chris Rigg 162,059 0.10
Dr. John Brown 73,529 0.04
Ian Johnson 58,824 0.03
Christopher Mills** 0 0.00

** Christopher Mills, who is a Non-executive Director of Quantum Pharma Plc, is the Chief Executive of North Atlantic Smaller Companies Investment Trust plc, Director of Oryx International Growth Fund Limited and also Chief Executive Officer of Harwood Capital LLP (see Major shareholders above).

Shares not in public hands

In terms of AIM Rules published July 2016 and insofar as it is aware, as at 30 June 2017, 30.13% of the Company's AIM securities was not in public hands.

Restrictions in transfer of AIM securities

There are no restrictions on the transfer of securities.

UK City Code on Takeovers and Mergers

Quantum Pharma Plc is subject to the UK City Code on Takeovers and Mergers.

Details of other exchanges or trading platforms

Other than AIM, the Company's shares are not admitted to or traded on any other exchanges or trading platforms.

 

Page last updated: 19 July 2017

 
Quantum Pharmaceuticals
UL Medicines
Quantum Aseptics
PERN Consumer Products
PROTOMED